Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01416844 | Study of Immune Responses in Patients With Metastatic Melanoma | withdrawn | Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT00288041 | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00005961 |
| O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma |
| completed |
| Phase 2 |
| 40 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Feb 11, 2013 |
| clinicaltrials |
| NCT00017316 | Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT01782508 | A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00003911 | S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 31, 2013 | clinicaltrials |
| NCT01216787 | RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00036764 | BMS-247550 in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00006003 | SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00072345 | Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00072163 | Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00004152 | PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00004250 | Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00005949 | Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00024011 | PS-341 in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00204516 | Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens | completed | Phase 1 / Phase 2 | 31 | University Hospital TuebingenOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00204594 | Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28 | completed | Phase 1 / Phase 2 | 1 | University Hospital TuebingenOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00119249 | Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00509496 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00509288 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00001832 | Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma | completed | Phase 2 | 170 | National Cancer Institute (NCI)NIH | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00003802 | Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma | completed | Phase 2 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT00085579 | Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 12, 2012 | clinicaltrials |
| NCT00627419 | A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma | terminated | Phase 2 | 1 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 10, 2012 | clinicaltrials |
| NCT00835419 | Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression(ENVER) | completed | Phase 2 | 12 | Piramal Enterprises LimitedINDUSTRY | 3 | Dec 4, 2012 | clinicaltrials |
| NCT00328861 | Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2012 | clinicaltrials |
| NCT00924001 | Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 25, 2012 | clinicaltrials |
| NCT00059475 | Peptide Vaccination for Patients at High Risk for Recurrent Melanoma | completed | Phase 2 | 138 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2012 | clinicaltrials |
| NCT00273910 | Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | completed | Phase 2 | 104 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2012 | clinicaltrials |
| NCT00314106 | Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2012 | clinicaltrials |
| NCT01331915 | Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients(THERAVAC) | unknown | Phase 1 / Phase 2 | 23 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00512798 | Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | terminated | Phase 1 / Phase 2 | 47 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 2, 2012 | clinicaltrials |
| NCT00005615 | Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa | completed | Phase 1 / Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT00003828 | S9804: Vinorelbine in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 24 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 22, 2012 | clinicaltrials |
| NCT00104988 | S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 22, 2012 | clinicaltrials |
| NCT00062933 | A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2012 | clinicaltrials |
| NCT00014625 | E7070 in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 28 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 24, 2012 | clinicaltrials |
| NCT00085059 | Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 4 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00003989 | ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma | completed | Phase 2 | 50 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00002669 | Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 2, 2012 | clinicaltrials |
| NCT00094107 | Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma | completed | Phase 2 | 32 | PfizerINDUSTRY | 2 | Jun 26, 2012 | clinicaltrials |
| NCT00077532 | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 179 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jun 22, 2012 | clinicaltrials |
| NCT00080353 | Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00295958 | LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 26 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00846833 | Haploidentical NK Cell Infusion in Malignant Melanoma | completed | Phase 1 / Phase 2 | 12 | Seoul National University HospitalOTHER | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00254579 | Study of CP-675,206 in Refractory Melanoma | completed | Phase 2 | 251 | AstraZenecaINDUSTRY | 9 | Jun 7, 2012 | clinicaltrials |
| NCT00281541 | A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma | completed | Phase 2 | 29 | Astellas Pharma IncINDUSTRY | 1 | Jun 7, 2012 | clinicaltrials |
| NCT01614301 | Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 136 | University of RegensburgOTHER | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00086489 | CP-675,206 In Patients With Advanced Melanoma | completed | Phase 2 | 118 | AstraZenecaINDUSTRY | 1 | Jun 6, 2012 | clinicaltrials |
| NCT01026051 | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma | terminated | Phase 2 | 5 | Mannkind CorporationINDUSTRY | 1 | May 15, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Mar 7, 2013source: clinicaltrials